Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His Cyclic (2->9)-Disulfide
Breast Carcinoma
Explore 209 assets in Breast Carcinoma →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Spexis AG
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03786094CT.gov Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His Cyclic (2->9)-Disulfide (this asset) | Spexis AG | P3 | B · 59 |
| Trastuzumab | SWOG Cancer Research Network | P4 | BBB |
| Zoledronate | Washington University School of Medicine | P4 | BBB |
| Trastuzumab Deruxtecan | SWOG Cancer Research Network | P4 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P3 | BBB |
| Tamoxifen | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BBB |
| Olaparib | The Netherlands Cancer Institute | P4 | BBB |
| Dexasone | Tianjin Medical University Cancer Institute and Hospital | P4 | BBB |
+42 more in the Breast Carcinoma cohort
Other indications for Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His Cyclic (2->9)-Disulfide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | B · 59 |
| Plasma Cell Myeloma | — | P2 | CCC · 53 |
| Acute Myeloid Leukemia | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ala-Cys-Ser-Ala-Pro-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro-Tyr-His Cyclic (2->9)-Disulfide in Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ala-cys-ser-ala-pro-arg-tyr-cys-tyr-gln-lys-pro-pro-tyr-his-cyclic-2-9-disulfide-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →